Evaluation of anti- fibrosis effect of compound Biejia Ruangan tablets with transient elastography

Objective To evaluate the clinical efficacy of compound Biejia Ruangan tablets using transient elastography in patients with hepatitis B- induced compensated liver cirrhosis who are concurrently treated with entecavir. Methods In this prospective, randomized, and controlled study, 100 patients with hepatitis B- induced compensated liver cirrhosis were randomly assigned to the control group and the experimental group in a ratio of 1: 1. The patients in the control group were treated with the anti- virus drug entecavir alone, whereas the patients in the experimental group were treated with entecavir and compound Biejia Ruangan tablets for anti- fibrosis therapy. The patients were followed up at 6 and 12months. After treatment, the changes in transient elasticity values were evaluated, and the transient elasticity values were compared between the two groups. Continuous variables were compared with the t test and categorical data as well as rates were compared with the chi- square test. Results Treatment with compound Biejia Ruangan tablets led to significantly lower transient elasticity values in the experimental group than in the control group at 6 and 12 months ( t = 2. 963, P = 0. 004; t = 2. 239, P = 0. 027) . Transient elasticity values at 6 and 12 months were significantly lower than their respective baseline levels in the control group ( t = 4. 295, P < 0. 001 for comparison between values at baseline and 6months; t = 6. 109, P < 0. 001 for comparison between values at baseline and 12 months; t = 5. 394, P < 0. 001 for comparison between values at 6 and 12 months) and the experimental group ( t = 8. 505, P < 0. 001 for comparison between values at baseline and 6 months; t = 9. 882, P<0. 001 for comparison between values at baseline and 12 months; t = 7. 930, P < 0. 001 for comparison between values at 6 months and 12months) . At 12 months, the proportion of patients with liver cirrhosis in the experimental group was significantly lower than that in the control group ( χ2= 4. 058, P = 0. 044) . Conclusion Entecavir can relieve liver fibrosis to some extent. Moreover, entecavir combined with compound Biejia Ruangan tablets can lead to further improvement in liver fibrosis at 6 and 12 months.